Publications by authors named "Ryan D Cassaday"

Claim this Profile
O
Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.
Ibrahim Aldoss, Amir Ali, Ryan D Cassaday, Emily K Curran, Marlise R Luskin

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.
Emily Curran, Marlise R Luskin, Houda Alachkar, Ibrahim Aldoss, Patrick W Burke, Ryan D Cassaday

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia.
Ryan D Cassaday

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL.
Ryan D Cassaday

Hematology Am Soc Hematol Educ Program· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.
Suravi Raychaudhuri, Ryan D Cassaday, Mary-Elizabeth M Percival

Hematology Am Soc Hematol Educ Program· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Katharine Miller, Ryan D Cassaday

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy.
Sai Kit Ng, Patrick W Flaherty, Melissa Ancheta, Karyn A Tindbaek, Mandeep K Sekhon, Ryan D Cassaday

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, Andrew J Cowan, Edus H Warren

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.
Muhit Özcan, Ryan D Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang

Ther Adv Med Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up.
Andrew J Portuguese, Jennifer J Huang, Yein Jeon, Mahnoosh Taheri, Aya Albittar, Ryan D Cassaday

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.
Muhit Özcan, Ryan D Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang

Haematologica· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Ibrahim N Muhsen, Gregory W Roloff, Rawan Faramand, Tamer Othman, Yannis Valtis, Ryan D Cassaday

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
Suravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Ryan D Cassaday

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world performance of the CALGB 10403 regimen in young adults in the United States.
Brandon DaSilva, Alicia Darwin, Amy Zhang, Rutu D Vyas, Kathryn Russell, Ryan D Cassaday

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.
Elias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, Anna Torrent, José J Rifón, Ryan D Cassaday

Lancet Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Hannah Lust, Liora M Schultz, Soyang Kwon, Gregory W Roloff, Ibrahim Aldoss, Ryan D Cassaday

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Aaron C Logan

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary.
David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park

Expert Rev Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.
Jordan Gauthier, Emily C Liang, Jennifer J Huang, Erik L Kimble, Alexandre V Hirayama, Ryan D Cassaday

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker, Ryan D Cassaday

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar, Ryan D Cassaday

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
Noam E Kopmar, Xiaoyu Qu, Yajuan Liu, Ted A Gooley, Cristina M Ghiuzeli, Ryan D Cassaday

Leuk Lymphoma· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review.
David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park

Expert Rev Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin, Ryan D Cassaday

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Noam E Kopmar, Ryan D Cassaday

Cancer Manag Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis